Skip to main content

Advertisement

SpringerLink
Log in

Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The increasing number of resistant bacterial strains in infective endocarditis (IE) emphasizes the need for a constant development of antimicrobials. Linezolid is an oxazolidinone with an effect on Gram-positive cocci. Only a few casuistic reports describe its utilization in the treatment of IE. The objective of this study is to report our experience with linezolid from a large consecutive cohort of IE patients. In a retrospective cohort study, data on 550 consecutive IE patients were collected at two tertiary University Hospitals in Copenhagen, Denmark. The main endpoints were differences in the in-hospital and 12 months post-discharge mortality between IE patients receiving linezolid for a part of the treatment and IE patients receiving conventional treatment. Of the 550 patients enrolled in the study, 38 patients received linezolid treatment and 512 received conventional treatment. Reasons for adding linezolid were antibiotic intolerance (n = 13), nephrotoxicity (n = 5), pharmaceutical interactions (n = 1), inadequate clinical response (n = 14), or inadequate microbial response (n = 5). No significant differences in the cure rate (74 % vs. 71 %, p > 0.05), in-hospital mortality (13 % vs. 14 %, p > 0.05), or post-discharge mortality at 12 months follow-up (26 % vs. 26 %, p > 0.05) were observed. In the current study, we found that linezolid, in general, was well tolerated and associated with the same outcome as in patients with Gram-positive IE treated with other antibiotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135–142

    PubMed  CAS  Google Scholar 

  2. Rubinstein E, Isturiz R, Standiford HC et al (2003) Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 47:1824–1831

    Article  PubMed  CAS  Google Scholar 

  3. Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59:S59–S74

    Article  PubMed  Google Scholar 

  4. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL et al (2001) Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 47:349–352

    Article  PubMed  CAS  Google Scholar 

  5. Patel R, Rouse MS, Piper KE et al (2001) Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 45:621–623

    Article  PubMed  CAS  Google Scholar 

  6. Tsaganos T, Skiadas I, Koutoukas P et al (2008) Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 62(2):381–383

    Article  PubMed  CAS  Google Scholar 

  7. Mancino P, Ucciferri C, Falasca K et al (2008) Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. Scand J Infect Dis 40:67–73

    Article  PubMed  CAS  Google Scholar 

  8. Muñoz P, Rodríguez-Creixéms M, Moreno M et al (2007) Linezolid therapy for infective endocarditis. Clin Microbiol Infect 13:211–215

    Article  PubMed  Google Scholar 

  9. Lauridsen TK, Arpi M, Bruun NE (2010) Linezolid therapy for infectious endocarditis. Ugeskr Laeger 172(16):1215–1216

    PubMed  Google Scholar 

  10. Buchholtz K, Larsen CT, Hassager C et al (2009) Severity of gentamicin’s nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48(1):65–71

    Article  PubMed  Google Scholar 

  11. Durack DT, Lukes AS, Bright DK (1994) New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis service. Am J Med 96(3):200–209

    Article  PubMed  CAS  Google Scholar 

  12. Li JS, Sexton DJ, Mick N et al (2000) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30(4):633–638

    Article  PubMed  CAS  Google Scholar 

  13. National Committee for Clinical Laboratory Standards (NCCLS) (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—fifth edition: approved standard M7-A5. NCCLS, Wayne, PA

    Google Scholar 

  14. National Committee for Clinical Laboratory Standards (NCCLS) (2000) Performance standards for antimicrobial susceptibility testing—tenth informational supplement, M100-S10. NCCLS, Wayne, PA

    Google Scholar 

  15. Noskin GA, Siddiqui F, Stosor V et al (1999) In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 43(8):2059–2062

    PubMed  CAS  Google Scholar 

  16. Zaoutis T, Moore LS, Furness K et al (2001) In vitro activities of linezolid, meropenem, and quinupristin–dalfopristin against Group C and G streptococci, including vancomycin-tolerant isolates. Antimicrob Agents Chemother 45(7):1952–1954

    Article  PubMed  CAS  Google Scholar 

  17. Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49:467–470

    Article  PubMed  CAS  Google Scholar 

  18. Habib G, Hoen B, Tornos P et al; ESC Committee for Practice Guidelines (2009) Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 19:2369–2413

    Google Scholar 

  19. Bruun NE, Egeblad H, Elming H, Fuursted K, Hassager C, Helweg-Larsen J, et al. NBV 2011, http://www.cardio.dk/nbv/infektios-endocarditis

  20. World Health Organization (WHO) (2003) WHO toxicity grading scale for determining the severity of adverse events. Available online at: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%20final.pdf

  21. Vardakas KZ, Kioumis I, Falagas ME (2009) Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metab 10:2–12

    Article  PubMed  CAS  Google Scholar 

  22. Gould FK (2011) Linezolid: safety and efficacy in special populations. J Antimicrob Chemother 66(Suppl 4):iv3–iv6

    Article  PubMed  CAS  Google Scholar 

  23. Bressler AM, Zimmer SM, Gilmore JL et al (2004) Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4:528–531

    Article  PubMed  Google Scholar 

  24. Brown J, Aitken SL, van Manen RP (2011) Potential for linezolid-related blindness: a review of spontaneous adverse event reports. Pharmacotherapy 31(6):585–590

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The corresponding author had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. There are no conflicts of interest for any of the authors.

Author information

Authors and Affiliations

  1. Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark

    T. K. Lauridsen, H. Bundgaard & C. Hassager

  2. Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark

    L. E. Bruun, N. Risum & N. E. Bruun

  3. Department of Cardiology, Hvidovre University Hospital, Copenhagen, Denmark

    R. V. Rasmussen

  4. Department of Clinical Microbiology, Herlev University Hospital, Herlev, Denmark

    M. Arpi

  5. Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark

    C. Moser & H. K. Johansen

Authors
  1. T. K. Lauridsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. E. Bruun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. V. Rasmussen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Arpi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Risum
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Moser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. K. Johansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Bundgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Hassager
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N. E. Bruun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. K. Lauridsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lauridsen, T.K., Bruun, L.E., Rasmussen, R.V. et al. Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study. Eur J Clin Microbiol Infect Dis 31, 2567–2574 (2012). https://doi.org/10.1007/s10096-012-1597-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-012-1597-7

Keywords

Search

Navigation